• 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>World journal of urology >Efficacy of intra-arterial chemotherapy combined with intravesical chemotherapy in T1G3 bladder cancer when compared with intravesical chemotherapy alone after bladder-sparing surgery: a retrospective study
【24h】

Efficacy of intra-arterial chemotherapy combined with intravesical chemotherapy in T1G3 bladder cancer when compared with intravesical chemotherapy alone after bladder-sparing surgery: a retrospective study

机译：动脉内化疗联合T1G3膀胱癌中膀胱内化疗的疗效与膀胱缺乏术后单独的膀胱术治疗相比：回顾性研究

获取原文
获取原文并翻译 | 示例
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

PurposeTo assess the efficacy of intra-arterial chemotherapy (IAC) combined with intravesical chemotherapy (IVC) in T1G3 bladder cancer (Bca) after transurethral resection of bladder tumor (TURBT).MethodsOur study retrospectively reviewed 200 patients with T1G3 BCa who had all undergone TURBT. The patients' medical records were divided into two groups, one group only had IVC with pirarubicin after surgery, and the other group had IAC (cisplatin and epirubicin) combined with IVC after surgery. The patients were monitored regularly by urine cytology and cystoscopy. Survival and recurrence curves were calculated using the Kaplan-Meier method. Tumor recurrence, progression and tumor-specific death rate were compared with Chi-square test. A multivariate analysis was carried out to find out potential confounders.ResultsA total of 200 medical record was analyzed, 131 patients received IVC, 69 IAC+IVC treatment, tumor-specific death rate between the combined IAC and IVC compared to IVC alone was 7.25 and 17.6%, respectively (p<0.05); the tumor recurrence rate between the two groups was 31.8% (22/69) and 44.3%, respectively (58/131) (p<0.05), and tumor recurred later in the IAC+IVC group (p<0.05), tumor progression rate was 18.8% (13/69) and 28.2% (37/131), respectively, with p<0.05. Overall survival was longer in IAC+IVC group (p<0.05). Using the multivariable regression model, IAC was significantly related to disease recurrence (p<0.05) and overall survival (p<0.05).ConclusionT1G3 BCa post-TURBT surgery patients who underwent IAC combined with IVC had a longer overall survival and increased time interval to first recurrence, lower tumor recurrence rate, progression rate and tumor-specific death rate than compared with those who only underwent IVC alone.
机译：Purposeto评估动脉内化疗（IAC）与T1G3膀胱癌（BCA）中的膀胱内化疗（IVC）联合在膀胱肿瘤（TurBT）中的膀胱内化疗（BCA）结合的疗效.Methodsour研究回顾性地审查了200例T1G3 BCA患者，他们都经过了TURBT 。将患者的病历分为两组，一组只有IVC患有手术后含有吡咯比蛋白，而另一组患有IAC（顺铂和同性素）与IVC一起进行手术后。通过尿液细胞学和膀胱镜检查定期监测患者。使用Kaplan-Meier方法计算存活率和复发曲线。将肿瘤复发，进展和肿瘤特异性死亡率与Chi-Square试验进行比较。进行多元分析以找出潜在的混淆。分析了200名医学记录的潜在混淆，131名患者接受IVC，69次IAC + IVC治疗，与单独的IVC相比，IAC和IVC之间的肿瘤特异性死亡率为7.25和分别为17.6％（P <0.05）;两组之间的肿瘤复发率分别为31.8％（22/69）和44.3％（58/131）（P <0.05），肿瘤患者在IAC + IVC组中重复（P <0.05），肿瘤进展速率为18.8％（13/69）和28.2％（37/131），P <0.05。 IAC + IVC组总存活较长（P <0.05）。使用多变量回归模型，IAC与疾病复发有显着相关（P <0.05）和总存活（P <0.05）.ConclusionT1G3 BCA后Turbt接受IVC联合IVC的患者的总生存率和增加的时间间隔。首先复发，较低的肿瘤复发率，进展率和肿瘤特异性死亡率，而不是与单独接受IVC的人相比。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号